Furiex Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1998-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://furiex.com
Clinical Trials
9
Active:2
Completed:5
Trial Phases
3 Phases
Phase 2:4
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 3
2 (28.6%)Not Applicable
1 (14.3%)Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 1146
- Registration Number
- NCT01553747
- Locations
- 🇬🇧
Furiex Research Site, Wigan, United Kingdom
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 1282
- Registration Number
- NCT01553591
- Locations
- 🇬🇧
Furiex Research Site, Torpoint, United Kingdom
🇺🇸Furix Research Site, Hialeah, Florida, United States
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
Phase 2
Completed
- Conditions
- MyalgiaHypercholesterolemiaHyperlipidemia
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 282
- Registration Number
- NCT01279590
- Locations
- 🇺🇸
Furiex research site, Richmond, Virginia, United States
🇺🇸Furiex Research site, Boise, Idaho, United States
🇺🇸Furiex, Spokane, Washington, United States
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Phase 2
Terminated
- Conditions
- Community-Acquired Bacterial Pneumonia (CABP)
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01198626
- Locations
- 🇵🇱
Furiex Research Site, Warszawa, Poland
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 807
- Registration Number
- NCT01130272
- Locations
- 🇺🇸
Furiex Research Site, Milwaukee, Wisconsin, United States
- Prev
- 1
- 2
- Next
News
No news found